Helaina is a biotech company founded in 2019 that uses precision fermentation technology to recreate proteins found in human breast milk. The company's flagship product is Effera, a human lactoferrin protein that claims to be 99% identical to the one found in natural breast milk. Helaina's process involves programming yeast to produce these proteins during fermentation by introducing human DNA. The resulting product is a pure, functional protein that can be used in infant formula and other nutritional products.
Helaina's technology aims to bridge the gap between traditional infant formula and breastfeeding by providing immune-equivalent proteins that offer claimed benefits such as improved nutrient absorption, cognitive support, and antimicrobial defense.
In May 2023, Helaina announced it had achieved commercial-scale production of lactoferrin, producing over 75,000 servings. Following this, the company has successfully manufactured over 200,000 servings of Effera as of January 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.